Biogen (BIIB) Competitors $125.94 -0.14 (-0.11%) As of 09:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BIIB vs. REGN, ALNY, INCY, UTHR, NBIX, EXEL, BMRN, EXAS, RGEN, and HALOShould you be buying Biogen stock or one of its competitors? The main competitors of Biogen include Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Repligen (RGEN), and Halozyme Therapeutics (HALO). These companies are all part of the "biotechnology" industry. Biogen vs. Its Competitors Regeneron Pharmaceuticals Alnylam Pharmaceuticals Incyte United Therapeutics Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Exact Sciences Repligen Halozyme Therapeutics Regeneron Pharmaceuticals (NASDAQ:REGN) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment. Is REGN or BIIB more profitable? Regeneron Pharmaceuticals has a net margin of 31.94% compared to Biogen's net margin of 15.07%. Regeneron Pharmaceuticals' return on equity of 15.27% beat Biogen's return on equity.Company Net Margins Return on Equity Return on Assets Regeneron Pharmaceuticals31.94% 15.27% 11.93% Biogen 15.07%14.03%8.32% Which has more volatility & risk, REGN or BIIB? Regeneron Pharmaceuticals has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.14, meaning that its share price is 86% less volatile than the S&P 500. Do analysts prefer REGN or BIIB? Regeneron Pharmaceuticals currently has a consensus price target of $813.57, suggesting a potential upside of 54.96%. Biogen has a consensus price target of $188.48, suggesting a potential upside of 50.08%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Regeneron Pharmaceuticals is more favorable than Biogen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regeneron Pharmaceuticals 1 Sell rating(s) 6 Hold rating(s) 15 Buy rating(s) 3 Strong Buy rating(s) 2.80Biogen 0 Sell rating(s) 20 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.38 Which has better earnings and valuation, REGN or BIIB? Regeneron Pharmaceuticals has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRegeneron Pharmaceuticals$14.20B3.99$4.41B$39.2813.37Biogen$9.68B1.90$1.63B$10.1312.40 Does the media prefer REGN or BIIB? In the previous week, Biogen had 3 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 40 mentions for Biogen and 37 mentions for Regeneron Pharmaceuticals. Biogen's average media sentiment score of 0.95 beat Regeneron Pharmaceuticals' score of 0.81 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 17 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 3 Very Negative mention(s) Positive Biogen 21 Very Positive mention(s) 2 Positive mention(s) 14 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in REGN or BIIB? 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 0.2% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryRegeneron Pharmaceuticals beats Biogen on 14 of the 17 factors compared between the two stocks. Get Biogen News Delivered to You Automatically Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BIIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIIB vs. The Competition Export to ExcelMetricBiogenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.47B$2.84B$5.45B$8.90BDividend YieldN/A2.70%5.36%4.13%P/E Ratio12.4021.1526.4219.67Price / Sales1.90259.81406.85110.30Price / Cash5.4641.2925.8827.49Price / Book1.097.247.915.42Net Income$1.63B-$55.05M$3.15B$248.34M7 Day Performance-0.57%-1.01%0.62%0.81%1 Month Performance-4.21%5.98%4.94%5.01%1 Year Performance-45.81%0.83%32.26%18.10% Biogen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIIBBiogen4.9528 of 5 stars$125.94-0.1%$188.48+49.7%-45.8%$18.38B$9.68B12.387,605REGNRegeneron Pharmaceuticals4.9315 of 5 stars$511.66+0.4%$836.48+63.5%-50.0%$55.24B$14.20B13.0315,106Analyst DowngradeALNYAlnylam Pharmaceuticals4.2615 of 5 stars$314.21+1.5%$319.58+1.7%+34.2%$40.97B$2.25B-150.342,230Positive NewsAnalyst ForecastINCYIncyte4.3408 of 5 stars$67.63-1.2%$74.53+10.2%+12.3%$13.13B$4.24B212.012,617UTHRUnited Therapeutics4.9941 of 5 stars$286.02-1.6%$393.08+37.4%-9.8%$12.90B$2.88B11.411,305Analyst ForecastNBIXNeurocrine Biosciences4.9115 of 5 stars$127.34+0.6%$162.00+27.2%-8.7%$12.60B$2.36B43.151,800Positive NewsEXELExelixis4.6547 of 5 stars$43.80+8.5%$41.00-6.4%+96.2%$11.95B$2.17B19.911,147Positive NewsAnalyst ForecastGap UpHigh Trading VolumeBMRNBioMarin Pharmaceutical4.9491 of 5 stars$54.23-1.4%$93.45+72.3%-33.2%$10.43B$2.95B20.223,040EXASExact Sciences4.8659 of 5 stars$52.27-1.4%$70.90+35.6%+25.8%$9.88B$2.76B-9.517,000RGENRepligen4.7786 of 5 stars$117.89-0.8%$173.25+47.0%-1.3%$6.61B$634.44M-261.561,778Positive NewsAnalyst DowngradeHALOHalozyme Therapeutics4.8325 of 5 stars$52.72-0.2%$61.90+17.4%-0.6%$6.49B$1.02B14.02390Analyst Revision Related Companies and Tools Related Companies Regeneron Pharmaceuticals Competitors Alnylam Pharmaceuticals Competitors Incyte Competitors United Therapeutics Competitors Neurocrine Biosciences Competitors Exelixis Competitors BioMarin Pharmaceutical Competitors Exact Sciences Competitors Repligen Competitors Halozyme Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BIIB) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biogen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BIIB Stock Alerts